NCT07034521 The Feasibility and Therapeutic Effect of Hybrid End-effector Robot-assisted Gait Training With an Active-assisted Module in Chronic Stroke Survivors
| NCT ID | NCT07034521 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Taiwan University Hospital |
| Condition | Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-08-12 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2025-08-12 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Walking rehabilitation after stroke is most effective during the first three months of recovery, but even in the chronic phase-beyond six months post-stroke-a significant number of patients still show potential for gait improvement. Robot-assisted rehabilitation is becoming increasingly common in clinical settings, with various design modes available. However, the effectiveness of new products in improving gait or motor function still requires further investigation. This study aims to evaluate the usability and therapeutic effects of a new end-effector exoskeleton robot system, HIWIN MRG-P110, for gait training in chronic stroke patients. The system uses foot pedal mechanisms to drive hip and knee movements for lower-limb training. Unlike its predecessor, this device allows adjustment of the active assistance ratio, encouraging users to engage in voluntary movement. It is designed for gait training in stroke patients and others with neurological impairments, but the usability and efficacy of this new training model remain to be verified. This clinical trial is a randomized, single-blind, prospective study enrolling 60 stroke patients who are 6 months to 3 years post-onset and have a Functional Ambulation Category (FAC) level of 0 to 3. The study will explore how patients with varying degrees of motor weakness learn to adapt to the "active-assistive mode" in terms of speed and perception. Participants will be randomly assigned to either the active-assistive mode group or the fully passive mode group. Both groups will receive 15 treatment sessions over 5 weeks. The study will compare the two groups in terms of: 1. Improvements in gait and balance immediately post-treatment and at 3-month follow-up 2. Changes in brain activity, as measured by functional near-infrared spectroscopy (fNIRS)
Eligibility Criteria
Inclusion Criteria: * Aged between 18 and 80 years old. * First-ever stroke, confirmed by brain CT or MRI, with onset between 6 months and 3 years prior to enrollment. * Walking ability classified as Functional Ambulation Category (FAC) level 1 to level 3. * Prior to the current stroke, the participant was an independent community ambulator without mobility impairments. Exclusion Criteria: * Presence of lower limb joint contractures, deformities, or severe spasticity (Modified Ashworth Scale score of 4). * Lower limb musculoskeletal conditions causing wounds, pain, inability to bear weight, or significant leg length discrepancy (\>2 cm after orthotic correction). * Known history of osteoporotic fractures in the thoracolumbar spine or hip joints. * Inability to use the exoskeleton device due to body size, including: Body weight \> 135 kg; Thigh length \< 36 cm or \> 48 cm; Calf length \< 42 cm or \> 58 cm * Cognitive or communication impairments that prevent understanding of study instructions or completion of questionnaires. * Acute infections or unstable vital signs. * Significant orthostatic hypotension or inability to maintain upright posture for more than 30 minutes. * Use of indwelling urinary catheter or tracheostomy. * Pregnant women. * Terminal illness with life expectancy less than six months. * Inability to attend 15 rehabilitation sessions and follow-up assessment at 3 months.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07034521 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07034521 currently recruiting?
Yes, NCT07034521 is actively recruiting participants. Contact the research team at b00401020@ntu.edu.tw for enrollment information.
Where is the NCT07034521 trial being conducted?
This trial is being conducted at Taipei, Taiwan.
Who is sponsoring the NCT07034521 clinical trial?
NCT07034521 is sponsored by National Taiwan University Hospital. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.